HUTCHMED (China) (HMDCF) Other Non-Current Liabilities (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Other Non-Current Liabilities came in at $97.9 million in Q2 2026, up 5.2% year-over-year from $93.0 million in Q2 2025, and up 7.08% quarter-over-quarter from $91.4 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Other Non-Current Liabilities for 12 consecutive years, with $97.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 5.2% year-over-year to $97.9 million in Q2 2026; TTM through Jun 2026 was $97.9 million, a 5.2% increase from a year earlier, with the FY2025 full-year figure at $91.4 million, up 2066.72% from the prior year.
- Other Non-Current Liabilities was $97.9 million for Q2 2026 at HUTCHMED (China), up from $91.4 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $97.9 million in Q2 2026 and troughed at $4.2 million in Q4 2024.
- A 5-year average of $46.3 million and a median of $22.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slipped 4.53% in 2023 and surged 2066.72% in 2025, its largest moves.
- Over 5 years, Other Non-Current Liabilities stood at $25.2 million in 2022, then dropped by 23.43% to $19.3 million in 2023, then plunged by 78.13% to $4.2 million in 2024, then surged by 2066.72% to $91.4 million in 2025, then climbed by 7.08% to $97.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $97.9 million (Q2 2026), $91.4 million (Q4 2025), and $93.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 97.88 Mn |
| Dec 31, 2025 | 91.41 Mn |
| Jun 30, 2025 | 93.04 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Jun 30, 2024 | 19.31 Mn |
| Jun 30, 2023 | 19.29 Mn |
| Dec 31, 2022 | 25.20 Mn |
| Jun 30, 2022 | 20.21 Mn |
| Dec 31, 2021 | 11.56 Mn |
| Jun 30, 2021 | 5.52 Mn |
| Mar 31, 2021 | 6.81 Mn |
| Dec 31, 2020 | 8.78 Mn |
| Jun 30, 2020 | 9.01 Mn |
| Dec 31, 2019 | 5.96 Mn |
| Sep 30, 2019 | 7.46 Mn |
| Jun 30, 2019 | 7.86 Mn |
| Mar 31, 2019 | 8.33 Mn |
| Dec 31, 2018 | 2.40 Mn |
| Jun 30, 2018 | 2.85 Mn |
| Dec 31, 2017 | 1.12 Mn |